Skip to main content
Cellectis logo

Cellectis - Investor Relations & Filings

Listed IPO Feb 2007
Ticker · ALCLS ISIN · FR0010425595 LEI · 5493000KKX5VQ37Q2W83 PA Manufacturing
Open in API
Filings indexed 1,337 across all filing types
Latest filing 2025-11-07 Interim / Quarterly Rep…
Country FR France
Listing PA ALCLS · 12 venues

Key figures FY2025

Period ended 2025-12-31 · USD
Headline annual figures for Cellectis, fiscal year 2025, reported in USD, with the source filing for each figure.
Total Revenues USD 72.95M per the Earnings Release filed 2026-03-20
Net Income USD -67.59M per the Earnings Release filed 2026-03-20
Total Assets USD 324.72M per the Earnings Release filed 2026-03-20
Total Equity USD 75.90M per the Earnings Release filed 2026-03-20

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Cellectis

https://cellectis.com/en

Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.

Recent filings

Filing Released Lang Actions
Cellectis publie ses résultats financiers du troisième trimestre 2025 et une mise à jour de ses activités
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated November 7, 2025, from Cellectis presenting its financial results for the third quarter ending September 30, 2025, along with a business update. It includes detailed clinical trial data, financial cash position, and operational updates. The document contains substantive financial data such as cash balances, revenues, and expenses, as well as clinical program progress and future outlook. It is not merely an announcement of a report but contains actual financial results and operational details for the quarter. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-11-07 French
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
Earnings Release Classification · 100% confidence The document is a press release from Cellectis titled 'Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update'. It contains detailed financial highlights, pipeline updates, and management commentary regarding the quarter ending September 30, 2025. While it contains financial data, it is structured as an initial announcement of quarterly results rather than a full 10-Q or 10-K filing. According to the provided definitions, an 'Earnings Release' (ER) is the initial announcement of quarterly/periodical financial results, which matches this document perfectly. Q3 2025
2025-11-07 English
Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short, periodic disclosure titled 'Monthly information on share capital and company voting rights' pursuant to Article 223-16 of the French financial markets authority. It provides a table of total shares and voting rights as of a specific date. This type of regulatory disclosure regarding capital structure does not fit into specific categories like 'Share Issue' (which implies a change event) or 'Major Shareholding' (which implies a specific investor threshold). As it is a standard regulatory requirement for listed companies to publish this data periodically, it falls under the general regulatory filing category.
2025-11-07 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a monthly disclosure required by the AMF (Autorité des Marchés Financiers) regarding the total number of shares and voting rights. This type of regulatory disclosure, which provides transparency on capital structure, is classified as a general regulatory filing under the RNS category as it does not represent a specific corporate action like a dividend, share buyback, or major shareholding notification.
2025-11-07 French
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Cellectis S.A., pursuant to SEC rules. It references a press release dated November 3, 2025, attached as Exhibit 99.1. The document length is 2719 characters, which is relatively short and primarily serves as a cover report to submit the press release. There is no substantive financial data or detailed report content within this text itself. According to the MENU VS MEAL RULE, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such filings that do not fit other specific categories and are not full reports.
2025-11-03 English
Cellectis to Present a Development Update for eti-cel at ASH 2025
Regulatory Filings Classification · 100% confidence The document is a press release issued by Cellectis regarding the presentation of clinical trial data at the ASH 2025 conference. It provides updates on the development of specific drug candidates (eti-cel and lasme-cel) and includes forward-looking statements. It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate announcement of scientific progress and upcoming conference participation. As it does not fit into specific categories like 10-K, ER, or IR, it is classified as a general regulatory announcement/press release.
2025-11-03 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.